Aclarion (NASDAQ:ACON) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aclarion (NASDAQ:ACON) from a sell rating to a hold rating in a research note published on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Aclarion Price Performance

Shares of ACON stock opened at $2.52 on Friday. The stock has a market capitalization of $2.14 million, a price-to-earnings ratio of -0.17 and a beta of 1.44. The company’s fifty day simple moving average is $4.06 and its two-hundred day simple moving average is $6.16. Aclarion has a 1 year low of $2.34 and a 1 year high of $229.50.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.